| __timestamp | Novartis AG | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9086000000 | 7459000 |
| Thursday, January 1, 2015 | 8935000000 | 11831000 |
| Friday, January 1, 2016 | 9039000000 | 25705000 |
| Sunday, January 1, 2017 | 8972000000 | 46181000 |
| Monday, January 1, 2018 | 9074000000 | 59497000 |
| Tuesday, January 1, 2019 | 9402000000 | 65003000 |
| Wednesday, January 1, 2020 | 8980000000 | 74506000 |
| Friday, January 1, 2021 | 9540000000 | 126006000 |
| Saturday, January 1, 2022 | 9996000000 | 126215000 |
| Sunday, January 1, 2023 | 11371000000 | 120161000 |
| Monday, January 1, 2024 | 10022000000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Novartis AG has consistently demonstrated its strategic focus on R&D, with expenditures growing by approximately 25% from 2014 to 2023. In contrast, Protagonist Therapeutics, Inc., a smaller player, has shown a remarkable increase in R&D spending, surging by over 1,500% during the same period. This stark difference highlights the varying scales and strategies of these companies. While Novartis's R&D spending remains robust, Protagonist's rapid growth in investment underscores its aggressive pursuit of innovation. As the pharmaceutical industry continues to evolve, these trends in R&D spending will likely play a pivotal role in shaping the future of drug development and therapeutic breakthroughs.
R&D Insights: How Eli Lilly and Company and Protagonist Therapeutics, Inc. Allocate Funds
R&D Insights: How Novartis AG and Summit Therapeutics Inc. Allocate Funds
Comparing Innovation Spending: Novartis AG and Teva Pharmaceutical Industries Limited
R&D Spending Showdown: Novartis AG vs Sarepta Therapeutics, Inc.
Research and Development Investment: Novartis AG vs Madrigal Pharmaceuticals, Inc.
Comparing Innovation Spending: Novartis AG and PTC Therapeutics, Inc.
Research and Development Investment: ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.
R&D Insights: How CymaBay Therapeutics, Inc. and Protagonist Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Analyzing R&D Budgets: Perrigo Company plc vs Protagonist Therapeutics, Inc.
ImmunityBio, Inc. or Protagonist Therapeutics, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: Protagonist Therapeutics, Inc. vs Xencor, Inc.